Bugs living in the nose fight back against superbugs

Comment by Professor Colin Garner, Chief Executive, Antibiotic Research UK

Go to the profile of Antibiotic Research UK
Jul 28, 2016

According to reports a new class of antibiotics has been discovered by analysing bacteria in people’s noses. The University of Tubingen in Germany undertook the tests and the journal Nature reported the findings of the resulting drug, lugdunin which could treat superbug infections. The researchers at the University of Tubingen in Germany informed Nature that the human body is an untapped source of new drugs.

Professor Colin Garner, chief executive of Antibiotic Research UK, the world’s first charity established to tackle the threat of antibiotic resistance, says: "Altering the balance of bacteria in our bodies through the production of natural antibiotics could eventually be exploited to fight off bacterial infections. It is possible that this report will be the first of many demonstrating that bacteria in our bodies can produce novel antibiotics with new chemical structures.

“Alongside a report that men with beards have fewer pathogens including MRSA on their faces than clean-shaven men, it seems the paper identifying lugdunin should be viewed alongside facial hair as a preventer of infection. Perhaps stopping people picking their nose, and eating or swallowing snot, may actually be the wrong thing to do, as lugdunin and possibly other natural antibiotics might be fighting infections in our bodies all the time."

Further reading:


Go to the profile of Antibiotic Research UK

Antibiotic Research UK

ANTRUK, Charity

Antibiotic Research UK (ANTRUK) is a recently formed (mid-2014) charity which has as its mission 1) to educate the public and professionals about antibiotic resistance 2) to develop new antibiotic therapies and 3) to provide patient support to those affected by antibiotic resistant infections. The charity will commence its first research programme on Antibiotic Resistance Breakers in the first half of 2016. For more information please visit our website.

No comments yet.